Glyscend Inc

United Therapeutics Corporation is a biotechnology firm focused on the development and commercialization of innovative therapeutic products for patients with chronic and life-threatening cardiovascular, cancer and infectious diseases. The company develops technology platforms for prostacyclin analogs, immunotherapeutic monoclonal antibodies, glycobiology and telemedicine. It performs activities for cardiovascular health, including the development of analogs of the endogenous hormone prostacyclin for the treatment of pulmonary arterial hypertension and critical limb ischemia. United Therapeutics telemedicine services are focused on patients with an array of possible cardiac arrhythmias. The company s IMA therapies are designed to combat ovarian, prostate, breast, lung, pancreatic and colorectal cancers. Its glycobiology compounds target hepatitis C and other infectious diseases. United Therapeutics strategy is balanced among mature programs, pivotal development and early-stage pipeline activities. The company is headquartered in Silver Spring, Md.

Yiseng US Biopharma is a global biopharmaceutical company specializing in the discovery, development, manufacturing, and commercialization of vaccines and therapeutic biologics for infectious diseases and cancer. With a dedicated team of over 800 employees and a presence in multiple countries, including China, Singapore, the United States, the United Arab Emirates, and the Philippines, Yiseng US Biopharma utilizes its proprietary PIKA immunomodulating technology platform to develop a diverse range of biotherapeutics targeting diseases such as COVID-19, hepatitis B, rabies, flu, and various forms of cancer. Through their PIKA technology, which activates multiple pathways of immune signaling, including TLR3, RIG-I, and MDA5, Yiseng US Biopharma is at the forefront of developing innovative antiviral vaccines, antiviral therapeutics, and anticancer therapeutics. Their pipeline includes PIKA-based vaccines for infectious diseases and PIKA-based immuno-oncology candidates that have demonstrated potent antitumor effects in preclinical studies. With a strong focus on advancing novel immunotherapeutics, Yiseng US Biopharma is committed to making significant contributions to the field of biopharmaceuticals.Generated from the website

The Lieber Institute for Brain Development in Baltimore, MD, is dedicated to unlocking the mysteries of the brain through innovative research focused on various neurodevelopmental and psychiatric disorders, including schizophrenia, autism, and mood disorders. Their mission encompasses investigating the genetic, epigenetic, and environmental factors influencing brain health, with the ultimate goal of improving diagnosis and treatment while addressing health disparities in marginalized communities. Leveraging a diverse community of scientists, the institute also emphasizes the importance of early childhood development and the impact of environmental stressors on mental health. Through interdisciplinary approaches, they aim to advance understanding and treatment of addiction, suicide, and other critical issues affecting mental health in society. Generated from the website